Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Durable responses in aRCC, how do we optimise treatment?

Share :

Hot Topics in RCC

22 Apr - 30 Jul 2024
Published: 29 Jul 2024
Views: 1260
Rating:
Save
Prof Roberto Iacovelli and Prof Viktor Grünwald

This non-promotional, educational event has been organized and funded by Eisai Europe LTD., it is intended for Health Care Professionals only. This material is not intended for UK HCPs. Eisai products will be discussed.

Related Videos

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...
Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )
3 Jun 2024
EAU 2024: Bladder cancer latest
Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...
EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )
9 Apr 2024
A biomarker led approach to bladder cancer
Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...
A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )
22 Oct 2023
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...
Prof Nicolas Girard - Institut Curie, Paris, France
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )
11 Apr 2023
Four chemo cycles given with durvalumab and tremelimumab optimise response and...
Dr Niels Reinmuth - University of Muenster, Gauting, Germany
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )
6 Apr 2023
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...
Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )
6 Apr 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...
Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )
18 Feb 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation